Shots:

• The P-II/III ORIENT-32 study evaluates the efficacy & safety of sintilimab (200mg- q3w) + IBI305 (15 mg/kg- q3w) vs sorafenib (400 mg- PO- bid) as 1L treatment in patients in a ratio (2:1) with advanced HCC. The study was conducted at 50 clinical trial sites in China
• Results: improvements in OS & PFS with no new safety signals- combination regimen can provide a novel treatment option for patients while 1st interim analysis of OS showed a longer m-OS (not reached vs 10.4 mos.)
• The study is closed to new participants and follow-up is ongoing for long-term outcomes. The NMPA has accepted sNDA for sintilimab + bevacizumab biosimilar for HCC in Jan’21

  | Ref: PR Newswire | Image: Fierce Pharma